Related Experiment Video
Updated: Feb 11, 2026

A Simple Mechanical Procedure to Create Limbal Stem Cell Deficiency in Mouse
Published on: November 17, 2016
Targeting the Mevalonate Pathway Suppresses VHL-Deficient CC-RCC through an HIF-Dependent Mechanism
Jordan M Thompson1, Alejandro Alvarez1, Monika K Singha1
1Molecular Biology and Biochemistry Department, University of California Irvine, Irvine, California.
Abstract:
Clear cell renal cell carcinoma (CC-RCC) is a devastating disease with limited therapeutic options available for advanced stages. The objective of this study was to investigate HMG-CoA reductase inhibitors, also known as statins, as potential therapeutics for CC-RCC. Importantly, treatment with statins was found to be synthetically lethal with the loss of the von Hippel-Lindau (VHL) tumor suppressor gene, which occurs in 90% of CC-RCC driving the disease. This effect has been confirmed in three different CC-RCC cell lines with three different lipophilic statins. Inhibition of mevalonate synthesis by statins causes a profound cytostatic effect at nanomolar concentrations and becomes cytotoxic at low micromolar concentrations in VHL-deficient CC-RCC. The synthetic lethal effect can be fully rescued by both mevalonate and geranylgeranylpyrophosphate, but not by squalene, indicating that the effect is due to disruption of small GTPase isoprenylation and not the inhibition of cholesterol synthesis. Inhibition of Rho and Rho kinase (ROCK) signaling contributes to the synthetic lethality effect, and overactivation of hypoxia-inducible factor signaling resulting from VHL loss is required. Finally, statin treatment is able to inhibit both tumor initiation and progression of subcutaneous 786-OT1-based CC-RCC tumors in mice. Thus, statins represent potential therapeutics for the treatment of VHL-deficient CC-RCC. Mol Cancer Ther; 17(8); 1781-92. ©2018 AACR.
Insights
Statins, HMG-CoA reductase inhibitors, show promise as a new treatment for clear cell renal cell carcinoma (CC-RCC). They are synthetically lethal with von Hippel-Lindau (VHL) gene loss, a common CC-RCC driver.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Clear cell renal cell carcinoma (CC-RCC) presents limited treatment options for advanced stages.
- The von Hippel-Lindau (VHL) tumor suppressor gene is lost in 90% of CC-RCC cases, driving disease progression.
Purpose of the Study:
- To investigate HMG-CoA reductase inhibitors (statins) as potential therapeutics for CC-RCC.
- To explore the synthetic lethality between statins and VHL gene loss in CC-RCC.
Main Methods:
- Utilized three different CC-RCC cell lines and three lipophilic statins.
- Assessed the impact of statin treatment on VHL-deficient CC-RCC cell viability and tumor growth in mice.
- Investigated the rescue mechanisms of the synthetic lethal effect using mevalonate, geranylgeranylpyrophosphate, and squalene.
Main Results:
- Statin treatment demonstrated synthetic lethality with VHL loss in CC-RCC.
- Statins induced cytostatic and cytotoxic effects in VHL-deficient CC-RCC cells at nanomolar and micromolar concentrations, respectively.
- The synthetic lethality was attributed to the disruption of small GTPase isoprenylation, involving Rho/ROCK and HIF signaling pathways.
- Statin treatment inhibited tumor initiation and progression in a mouse model of CC-RCC.
Conclusions:
- Statins represent a potential therapeutic strategy for VHL-deficient CC-RCC.
- Targeting mevalonate synthesis and subsequent isoprenylation is a promising approach for CC-RCC treatment.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
cAMP-dependent Protein Kinase Pathways
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Frequency-dependent Selection
Reaction Mechanisms
For instance, the decomposition of ozone appears to follow a mechanism with two steps:
Drug Dependence

